Treating hyperglycemia is a critical aspect of managing type 2 diabetes mellitus (T2DM), but can be especially challenging in patients from vulnerable groups such as those with chronic evidence, it appears that the DPP-4 inhibitors are worthy of consideration not only for the most straightforward patients with T2DM, but also for these vulnerable patients.
INTRODUCTION
The prevalence and incidence of diabetes are increasing worldwide, largely due to changing lifestyles characterized by reduced physical activity, rising obesity rates, and an aging population. In the US, diabetes is the leading cause of kidney failure, new cases of blindness, and non-traumatic lower limb amputations, and is a major cause of heart disease and stroke [1] . Diabetes currently affects 8.3% of the US population, some 25.8 million people [1] , and type 2 diabetes mellitus (T2DM) accounts for about 90-95% of all diagnosed diabetes cases in adults.
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It is well documented that good glycemic control can positively influence much of the morbidity and mortality associated with T2DM [2] . To manage hyperglycemia, expert guidelines recommend treatment to a glycated hemoglobin (HbA1c) level of below 6.5% or below 7.0%, with recognition of the need for individualization of treatment goals, for example, to minimize the risks of hypoglycemia [2] [3] [4] . The percentage of US individuals with self-reported diabetes who achieved an HbA1c level of \7% increased from 44% in 1988-1994 to 52.5% in 2007-2010 [5] . Similarly, an observational study of non-insulin-treated patients with T2DM from Spain (n = 2,266) indicated that 45% had suboptimal HbA1c based on the \7%
criterion [6] . The International Diabetes Management Practices Study (IDMPS) of data from developing regions of Eastern Europe, Asia, and Latin America reported that 36.4% of participants with T2DM achieved an HbA1c of \7% [7] . These data were consistent with those from an observational study in Taiwan in which the percentage of patients achieving the \7% goal increased from 32.4% in 2006 to 34.5% in 2011 [8] . Taken together, these findings suggest that there has been some success in putting guidelines into practice, but that approximately one-third to one-half of patients still fail to achieve HbA1c levels below 7.0% [5] [6] [7] [8] .
Furthermore, the progressive deterioration of b-cell function, irrespective of pharmacological interventions to treat hyperglycemia, leads to an almost inevitable need for intensification of treatment [2] . There is, therefore, a recognized need for new therapeutic options that are well tolerated over the long term and have a durable effect.
The dipeptidyl peptidase (DPP)-4 inhibitors are relatively new drugs that may help meet the need for these types of treatments, and following extensive testing in phase 3 clinical trials, these agents have now been included in treatment recommendations in all major diabetes guidelines. This review will provide a brief overview regarding the positioning of DPP-4 inhibitors in the context of major clinical guidelines. Furthermore, since the majority of patients in phase 3 trials are relatively young and healthy, an additional objective of this review is to consider the DPP-4 inhibitors for the treatment of T2DM in more vulnerable patient populations, namely those with chronic kidney disease (CKD), African Americans, and older people. Current guidelines for these patients, and the clinical trials conducted with DPP-4 inhibitors in these groups, will be reviewed.
METHODS
This was a non-systematic review of the literature. A search of English-language literature was performed using PubMed and without imposing any time limitations. Search terms included combinations of the following:
'type 2 diabetes', 'DPP-4 inhibitors', 'chronic kidney disease', 'end-stage renal disease', 'renal impairment', 'African American', and 'elderly'.
Articles and abstracts relevant to the subject were included. Bibliographies from retrieved articles were also searched for relevant articles.
Additional references known to the author were also included. The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
DPP-4 INHIBITORS
The DPP-4 inhibitors improve glycemic control mainly via potentiation of the incretin effect, that is, the postprandial augmentation of insulin secretion by the gastrointestinal incretin hormones glucagon-like peptide (GLP)-
and gastric inhibitory polypeptide (GIP).
Increases in GLP-1 levels appear to account for the majority of the DPP-4 inhibitors' effects [9] .
In addition to enhancing glucose-dependent insulin secretion, GLP-1 suppresses glucosedependent glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake [10] . It has long been known that the incretin effect is blunted in patients with T2DM, generating interest in therapies that target the incretin system [10] . Native GLP-1 itself cannot be used in therapy due to its rapid degradation by the DPP-4 enzyme, resulting in a half-life of less than 2 min. Nevertheless, therapeutic approaches for enhancing incretin action have 
Place in Current Guidelines
In clinical trials, all available DPP-4 inhibitors have been shown to improve glycemic control, with clinically meaningful reductions in HbA1c [11] . Furthermore, they are well tolerated, are associated with a low risk of hypoglycemia, and have a favorable weight profile [11] . Individuals with concomitant T2DM and CKD may be receiving an ACEI for management of hypertension because this class of medications may reduce cardiovascular events and protect the kidney [2] . A small increase in the risk of angioedema has been observed in patients taking concurrent ACEI 
Use in African Americans
African Americans are at an increased risk of T2DM, with a prevalence of diabetes approximately double that of the white population [45] . This group also has an increased rate of complications and greater disability from complications, as well as poorer glycemic control and quality of care [46] [47] [48] [49] [50] .
The pathophysiology of T2DM may be different in African Americans than in other populations, with studies suggesting that insulin resistance is higher in minority populations [51] . There are various theoretical reasons to consider DPP-4 inhibitors in African Americans. First, a small number of studies report racial disparities in
GLP-1 levels that may have implications for efficacy of DPP-4 inhibitors in African
Americans. Two studies observed that African American adolescents had lower GLP-1 concentrations than white adolescents [52, 53] .
In contrast, an earlier investigation reported that obese African American adults had significantly higher fasting and post-challenge GLP-1 concentrations than obese white adults In the meantime, there are other reasons why DPP-4 inhibitors may be a good option for this population. A significant proportion of African Americans are overweight or obese, with the prevalence of overweight and obesity combined at 76.6% (69.9% in men, 82.1% in women), and the prevalence of obesity at 49.6% (38.8% in men, 58.6% in women) [55] . Overweight and obesity are risk factors for insulin resistance, and all guidelines therefore recommend losing weight for overweight or obese patients with T2DM [2] [3] [4] . In contrast to insulin and some oral antidiabetes drugs that can result in weight gain, the weight-neutral DPP-4 inhibitors may therefore be an appropriate option for patients who are overweight or obese. African Americans are also disproportionally affected by CKD and ESRD [56, 57] , with the rate of new ESRD cases being 3.4 times higher among this group than among the white population [21] . The presence of renal impairment has implications for diabetes management, but as discussed in the previous section, the DPP-4 inhibitors remain a viable choice in this setting. [61] . A subsequent phase 3 trial (NCT01194830) evaluated its efficacy and safety in black/African Americans with T2DM over 24 weeks [62] . In this study, 226 patients were randomized to linagliptin or placebo, and HbA1c levels were measured every 6 weeks. A statistically significant and clinically relevant difference American patients with T2DM [63] .
Use in Older People
The latest census figures in the US indicate that people aged 65 years and older represent 13.2% of the population [64] , and this proportion is expected to grow to just over 20% by 2050 [65] .
The incidence of T2DM in older people is a major public health concern, and in 2010 Three studies that prospectively assessed DPP-4 inhibitors in older patients with T2DM have been reported [71] [72] [73] (Table 4) . A doubleblind, randomized, active-controlled study compared vildagliptin with metformin over 24 weeks in 335 drug-naïve patients with T2DM aged C65 years. In this study, 41% of patients had normal renal function, 57% had mild renal insufficiency, and less than 2% had moderate renal insufficiency. The investigation showed that vildagliptin is an effective and well-tolerated treatment option in this group, demonstrating non-inferiority to metformin in terms of glycemic control, but superior gastrointestinal tolerability [71] . The second trial, a double-blind, randomized, placebocontrolled study of sitagliptin over 24 weeks in 206 patients with T2DM aged C65 years, concluded that sitagliptin significantly and rapidly improved glycemic control and was well tolerated in this group [72] . This study also included patients with moderate renal insufficiency (22%), but excluded those with severe renal insufficiency (estimated creatinine clearance \35 mL/min). Finally, a randomized, double-blind, placebo-controlled study investigated the efficacy and safety of linagliptin in 241 patients aged C70 years with T2DM and insufficient glycemic control despite metformin and/or sulfonylurea and/or insulin therapy [73] . The majority of patients in this study had either normal renal function (21%) or mild renal insufficiency (52%); 26% of patients had moderate renal insufficiency and less than 2% had severe renal insufficiency. This study concluded that linagliptin was effective and well tolerated in elderly patients and no safety concerns were identified.
Other pooled analyses, subgroup analyses, and systematic reviews also showed that DPP-4 inhibitors in the older T2DM population were generally effective and well tolerated [74] [75] [76] [77] [78] [79] [80] [81] .
However, some studies show that when DPP-4 inhibitors are concomitantly administered with insulin or a sulfonylurea, there is an elevated risk of hypoglycemia over the concomitant administration of placebo with insulin or a sulfonylurea [82, 83] . In contrast, a pooled analysis evaluating linagliptin as add-on therapy to basal insulin showed no increased risk of hypoglycemia with the DPP-4 inhibitor [81] . Given the serious consequences of hypoglycemic events in older patients, the combination of a DPP-4 inhibitor with a sulfonylurea is perhaps ill advised; in fact, the IAGG, EDWPOP, and the International Task Force of Experts in Diabetes recommend that sulfonylurea therapy should be avoided in any older patient at risk of hypoglycemia [69] .
Interestingly, there is also preliminary evidence that DPP-4 inhibitors are associated with a reduced risk of bone fractures compared with placebo or other treatments [84] . Recent evidence shows that T2DM is an independent risk factor for bone fracture [85, 86] and that older people with T2DM are at an increased risk of hip fractures [87, 88] . Furthermore, clinical trial data suggest that DPP-4 inhibitors may be associated with a lower risk of stroke compared with other therapies [89] . Patients with diabetes have an increased risk of ischemic stroke, a risk that increases in correlation with duration of diabetes [90, 91] , therefore posing a particular concern for elderly patients with long-standing T2DM. If confirmed, these risk reductions will provide further compelling reasons to consider DPP-4 inhibitors in older patients. Various prospective studies of glycemic outcomes in Table 4 Prospective phase 2/3 clinical trials of DPP-4 inhibitors in older patients (with published results) [97, 98] . In EXAMINE, the point estimate for the hazard ratio (HR) was \1
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and the upper limit of the 95% CI was \1.3, which was the pre-specified non-inferiority safety margin (HR with alogliptin, 0.96; upper boundary of the one-sided repeated CI, 1.16;
P\0.001 for non-inferiority) [97] . Similarly in SAVOR-TIMI 53, saxagliptin met the noninferiority criterion but did not demonstrate cardiovascular superiority versus placebo (HR with saxagliptin 1.00, 95% CI 0.89-1.12, P = 0.99 for superiority, P\0.001 for noninferiority) [98] . 
CONCLUSIONS

